AHRQ on osteoarthritis knee injections
This article was originally published in The Gray Sheet
Despite broad use, hyaluronic acid-based injections to treat osteoarthritis in the knee are not backed by high quality evidence of benefit, concludes the Agency for Healthcare Research and Quality in a 1report released Oct. 4. Existing trials "generally show positive effects" of the treatments on pain and function scores compared with placebo, and the relative risk appears to be low, but results are undermined by "variable trial quality, potential publication bias, and unclear clinical significance of the changes reported," AHRQ writes. The agency says a rigorous, randomized controlled trial is still needed. PMA-approved injections include Hyalgan (Sanofi-Aventis), Synvisc (Genzyme), Supartz (Smith & Nephew), Orthovisc (Anika Therapeutics) and Euflexxa (Ferring Pharmaceuticals)
You may also be interested in...
Unilever North America agrees SmartyPant, founded in 2011 to create a comprehensive supplement made from premium ingredients to support the wellbeing needs of children and adults. Kind, fully owned by Mars, has an agreement to acquire family-owned Nature's Bakery which offers snacks including fig bars and other soft-baked foods.
Arcadia prohibited from arguing against Advantice’s appeal of National Advertising Division decision that Kerasal Fungal Nail Renewal ad claims weren’t supported. Arcadia violated confidentiality rule by publicizing NAD decision before the review was officially closed.
The C-suite leaders schemed to falsely record shipments of unwanted products to distributors as sales so the company could meet revenue projections, the government charged.